Logo image of SCLX

SCILEX HOLDING CO (SCLX) Stock Fundamental Analysis

NASDAQ:SCLX - US80880W2052 - Common Stock

18.64 USD
+0.88 (+4.95%)
Last: 9/2/2025, 8:00:02 PM
18.69 USD
+0.05 (+0.27%)
After Hours: 9/2/2025, 8:00:02 PM
Fundamental Rating

2

SCLX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. SCLX may be in some trouble as it scores bad on both profitability and health. SCLX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SCLX had negative earnings in the past year.
SCLX had a negative operating cash flow in the past year.
SCLX had negative earnings in 4 of the past 5 years.
In the past 5 years SCLX always reported negative operating cash flow.
SCLX Yearly Net Income VS EBIT VS OCF VS FCFSCLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -164.82%, SCLX is doing worse than 86.15% of the companies in the same industry.
Industry RankSector Rank
ROA -164.82%
ROE N/A
ROIC N/A
ROA(3y)-63.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SCLX Yearly ROA, ROE, ROICSCLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 100 -100 200

1.3 Margins

SCLX has a Gross Margin of 66.45%. This is in the better half of the industry: SCLX outperforms 73.33% of its industry peers.
The Profit Margin and Operating Margin are not available for SCLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCLX Yearly Profit, Operating, Gross MarginsSCLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

SCLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SCLX Yearly Shares OutstandingSCLX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 1M 2M 3M 4M
SCLX Yearly Total Debt VS Total AssetsSCLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -11.89, we must say that SCLX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.89, SCLX is doing worse than 72.82% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.89
ROIC/WACCN/A
WACC9.6%
SCLX Yearly LT Debt VS Equity VS FCFSCLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M -100M

2.3 Liquidity

A Current Ratio of 0.19 indicates that SCLX may have some problems paying its short term obligations.
With a Current ratio value of 0.19, SCLX is not doing good in the industry: 95.90% of the companies in the same industry are doing better.
A Quick Ratio of 0.17 indicates that SCLX may have some problems paying its short term obligations.
With a Quick ratio value of 0.17, SCLX is not doing good in the industry: 95.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.17
SCLX Yearly Current Assets VS Current LiabilitesSCLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.81% over the past year.
EPS 1Y (TTM)85.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.55%

3.2 Future

Based on estimates for the next years, SCLX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.57% on average per year.
SCLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 75.38% yearly.
EPS Next Y80.66%
EPS Next 2Y46.84%
EPS Next 3Y32.54%
EPS Next 5Y20.57%
Revenue Next Year84.5%
Revenue Next 2Y136.81%
Revenue Next 3Y108.2%
Revenue Next 5Y75.38%

3.3 Evolution

SCLX Yearly Revenue VS EstimatesSCLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SCLX Yearly EPS VS EstimatesSCLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20 -30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

SCLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 5.88, the valuation of SCLX can be described as very cheap.
Based on the Price/Forward Earnings ratio, SCLX is valued cheaply inside the industry as 95.38% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of SCLX to the average of the S&P500 Index (22.52), we can say SCLX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 5.88
SCLX Price Earnings VS Forward Price EarningsSCLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCLX Per share dataSCLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SCLX's earnings are expected to grow with 32.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.84%
EPS Next 3Y32.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCLX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCILEX HOLDING CO

NASDAQ:SCLX (9/2/2025, 8:00:02 PM)

After market: 18.69 +0.05 (+0.27%)

18.64

+0.88 (+4.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)01-16 2026-01-16/amc
Inst Owners18.57%
Inst Owner Change-97.09%
Ins Owners0.47%
Ins Owner Change0%
Market Cap129.73M
Analysts80
Price Target499.8 (2581.33%)
Short Float %8.82%
Short Ratio2.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-132.24%
Min EPS beat(2)-256.34%
Max EPS beat(2)-8.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.81%
Min Revenue beat(2)-19.06%
Max Revenue beat(2)15.44%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)54.13%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.88
P/S 2.78
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.1
EYN/A
EPS(NY)3.17
Fwd EY17.02%
FCF(TTM)-3.02
FCFYN/A
OCF(TTM)-2.98
OCFYN/A
SpS6.72
BVpS-24.85
TBVpS-32.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -164.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.45%
FCFM N/A
ROA(3y)-63.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.96%
Cap/Sales 0.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.17
Altman-Z -11.89
F-Score2
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)20.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.07%
EPS Next Y80.66%
EPS Next 2Y46.84%
EPS Next 3Y32.54%
EPS Next 5Y20.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.55%
Revenue Next Year84.5%
Revenue Next 2Y136.81%
Revenue Next 3Y108.2%
Revenue Next 5Y75.38%
EBIT growth 1Y-375.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.59%
OCF growth 3YN/A
OCF growth 5YN/A